AcelRx Pharmaceuticals - ACRX Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AcelRx Pharmaceuticals stock.
View analyst ratings for AcelRx Pharmaceuticals or view top-rated stocks.

2 equities research analysts have issued 1 year price targets for AcelRx Pharmaceuticals' stock. Their ACRX stock forecasts range from $5.00 to $5.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 2,080.5% from the stock's current price.
View analysts' price targets for AcelRx Pharmaceuticals or view top-rated stocks among Wall Street analysts.

AcelRx Pharmaceuticals' stock was trading at $0.56 at the beginning of the year. Since then, ACRX shares have decreased by 59.1% and is now trading at $0.2293.
View the best growth stocks for 2022 here.

AcelRx Pharmaceuticals saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 11,210,000 shares, an increase of 81.4% from the June 30th total of 6,180,000 shares. Based on an average daily trading volume, of 2,070,000 shares, the short-interest ratio is presently 5.4 days.
View AcelRx Pharmaceuticals' Short Interest.

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its quarterly earnings data on Monday, May, 16th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, hitting analysts' consensus estimates of ($0.06). The specialty pharmaceutical company earned $0.44 million during the quarter, compared to analysts' expectations of $0.50 million. During the same period in the prior year, the company posted ($0.08) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

AcelRx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Values First Advisors Inc. (0.52%). Company insiders that own AcelRx Pharmaceuticals stock include Adrian Adams, Mark G Edwards and Vincent J Angotti.
View institutional ownership trends for AcelRx Pharmaceuticals.

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACRX stock can currently be purchased for approximately $0.23.

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $33.73 million and generates $2.82 million in revenue each year. The specialty pharmaceutical company earns $-35,100,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

AcelRx Pharmaceuticals employs 43 workers across the globe.

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for AcelRx Pharmaceuticals is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.